JP2002501762A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002501762A5 JP2002501762A5 JP2000530060A JP2000530060A JP2002501762A5 JP 2002501762 A5 JP2002501762 A5 JP 2002501762A5 JP 2000530060 A JP2000530060 A JP 2000530060A JP 2000530060 A JP2000530060 A JP 2000530060A JP 2002501762 A5 JP2002501762 A5 JP 2002501762A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- chain
- introduction agent
- lipophilic
- introduction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003795 chemical substances by application Substances 0.000 description 40
- 108020004707 nucleic acids Proteins 0.000 description 28
- 102000039446 nucleic acids Human genes 0.000 description 28
- 150000007523 nucleic acids Chemical class 0.000 description 28
- 125000001931 aliphatic group Chemical group 0.000 description 19
- 150000003431 steroids Chemical class 0.000 description 16
- 150000002632 lipids Chemical class 0.000 description 9
- 238000001890 transfection Methods 0.000 description 9
- 125000002091 cationic group Chemical group 0.000 description 7
- 230000009467 reduction Effects 0.000 description 7
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 239000004094 surface-active agent Substances 0.000 description 6
- 239000002671 adjuvant Substances 0.000 description 5
- -1 glycosyl diacylglycerol Chemical class 0.000 description 5
- 125000006850 spacer group Chemical group 0.000 description 5
- RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Substances C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 5
- 239000002253 acid Substances 0.000 description 4
- 125000004432 carbon atom Chemical group C* 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 238000010361 transduction Methods 0.000 description 4
- 230000026683 transduction Effects 0.000 description 4
- 125000000217 alkyl group Chemical group 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- 125000003118 aryl group Chemical group 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 229920000768 polyamine Polymers 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- JSPNNZKWADNWHI-PNANGNLXSA-N (2r)-2-hydroxy-n-[(2s,3r,4e,8e)-3-hydroxy-9-methyl-1-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoctadeca-4,8-dien-2-yl]heptadecanamide Chemical compound CCCCCCCCCCCCCCC[C@@H](O)C(=O)N[C@H]([C@H](O)\C=C\CC\C=C(/C)CCCCCCCCC)CO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O JSPNNZKWADNWHI-PNANGNLXSA-N 0.000 description 2
- YGPZWPHDULZYFR-DPAQBDIFSA-N (3s,8s,9s,10r,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-amine Chemical compound C1C=C2C[C@@H](N)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 YGPZWPHDULZYFR-DPAQBDIFSA-N 0.000 description 2
- 102000004506 Blood Proteins Human genes 0.000 description 2
- 108010017384 Blood Proteins Proteins 0.000 description 2
- KXDHJXZQYSOELW-UHFFFAOYSA-N Carbamic acid Chemical group NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 125000003368 amide group Chemical group 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 229930183167 cerebroside Natural products 0.000 description 2
- RIZIAUKTHDLMQX-UHFFFAOYSA-N cerebroside D Natural products CCCCCCCCCCCCCCCCC(O)C(=O)NC(C(O)C=CCCC=C(C)CCCCCCCCC)COC1OC(CO)C(O)C(O)C1O RIZIAUKTHDLMQX-UHFFFAOYSA-N 0.000 description 2
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 2
- 229960001231 choline Drugs 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- MWRBNPKJOOWZPW-CLFAGFIQSA-N dioleoyl phosphatidylethanolamine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(COP(O)(=O)OCCN)OC(=O)CCCCCCC\C=C/CCCCCCCC MWRBNPKJOOWZPW-CLFAGFIQSA-N 0.000 description 2
- 125000004185 ester group Chemical group 0.000 description 2
- 125000001033 ether group Chemical group 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- HVYWMOMLDIMFJA-UHFFFAOYSA-N 3-cholesterol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)CCCC(C)C)C1(C)CC2 HVYWMOMLDIMFJA-UHFFFAOYSA-N 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- FOCMISOLVPZNSV-CANPYCKCSA-N N-[(E,2R,3S)-1-[5-[5-[3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-hydroxyoctadec-4-en-2-yl]octadecanamide Chemical compound CCCCCCCCCCCCCCCCCC(=O)N[C@H](COC1OC(CO)C(OC2OC(CO)C(OC3OC(CO)C(O)C(O)C3NC(C)=O)C(O)C2O)C(O)C1O)[C@@H](O)\C=C\CCCCCCCCCCCCC FOCMISOLVPZNSV-CANPYCKCSA-N 0.000 description 1
- 102100021010 Nucleolin Human genes 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 239000004721 Polyphenylene oxide Substances 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- LEBBDRXHHNYZIA-LDUWYPJVSA-N [(2s,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] n-[(z)-1,3-dihydroxyoctadec-4-en-2-yl]carbamate Chemical group CCCCCCCCCCCCC\C=C/C(O)C(CO)NC(=O)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O LEBBDRXHHNYZIA-LDUWYPJVSA-N 0.000 description 1
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 125000002015 acyclic group Chemical group 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000000368 destabilizing effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 108020004084 membrane receptors Proteins 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- VELGMVLNORPMAO-JTFNWEOFSA-N n-[(e)-1-[(3r,4r,5s,6r)-5-[(2s,3r,4r,5r,6r)-5-[(2s,3r,4r,5r,6r)-3-acetamido-5-hydroxy-6-(hydroxymethyl)-4-[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,4-dihydroxy-6-(hydroxym Chemical group O[C@@H]1[C@@H](O)C(OCC(NC(=O)CCCCCCCCCCCCCCCCC)C(O)\C=C\CCCCCCCCCCCCC)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)[C@@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](CO)O1 VELGMVLNORPMAO-JTFNWEOFSA-N 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 108010044762 nucleolin Proteins 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229960000502 poloxamer Drugs 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920002477 rna polymer Polymers 0.000 description 1
- 150000003408 sphingolipids Chemical class 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9801065A FR2774394B1 (fr) | 1998-01-30 | 1998-01-30 | Composes transfectants sensibles aux conditions reductrices, compositions pharmaceutiques les contenant, et leurs applications |
| US7702698P | 1998-03-06 | 1998-03-06 | |
| US98/01065 | 1998-03-06 | ||
| US60/077,026 | 1998-03-06 | ||
| PCT/FR1999/000162 WO1999038821A2 (fr) | 1998-01-30 | 1999-01-28 | Composes transfectants sensibles aux conditions reductrices, compositions pharmaceutiques les contenant, et leurs applications |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002501762A JP2002501762A (ja) | 2002-01-22 |
| JP2002501762A5 true JP2002501762A5 (enExample) | 2009-09-17 |
Family
ID=26234096
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000530060A Pending JP2002501762A (ja) | 1998-01-30 | 1999-01-28 | 還元性条件に感受性のトランスフェクション用組成物、該組成物を含有する医薬組成物及びそれらの用途 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US6521252B1 (enExample) |
| EP (1) | EP1049793B1 (enExample) |
| JP (1) | JP2002501762A (enExample) |
| KR (1) | KR20010081924A (enExample) |
| CN (1) | CN1289371A (enExample) |
| AT (1) | ATE306556T1 (enExample) |
| AU (1) | AU759197B2 (enExample) |
| BR (1) | BR9907269A (enExample) |
| CA (1) | CA2318512C (enExample) |
| DE (1) | DE69927669T2 (enExample) |
| HU (1) | HUP0101393A3 (enExample) |
| IL (1) | IL137247A0 (enExample) |
| NO (1) | NO20003880L (enExample) |
| WO (1) | WO1999038821A2 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6169078B1 (en) * | 1998-05-12 | 2001-01-02 | University Of Florida | Materials and methods for the intracellular delivery of substances |
| US6379698B1 (en) * | 1999-04-06 | 2002-04-30 | Isis Pharmaceuticals, Inc. | Fusogenic lipids and vesicles |
| CA2424619C (en) * | 2000-10-04 | 2010-05-18 | Kyowa Hakko Kogyo Co., Ltd. | Method for coating fine particles with lipid membrane |
| CA2698812A1 (en) * | 2007-09-14 | 2009-03-19 | Nitto Denko Corporation | Drug carriers |
| FR2921369B1 (fr) * | 2007-09-25 | 2014-07-11 | Pf Medicament | Nouveau procede de preparation de derives (poly) aminoalkylaminoacetamide d'epipodophyllotoxine,utiles pour leurs applications en therapeutique comme agent anticancereux. |
| GB0720486D0 (en) * | 2007-10-19 | 2007-11-28 | Univ Edinburgh | Cationic lipids |
| US9765022B2 (en) * | 2013-02-28 | 2017-09-19 | Tufts University | Disulfide compounds for delivery of pharmaceutical agents |
| US11433128B2 (en) * | 2017-04-07 | 2022-09-06 | Tianxin Wang | Cell surface anchoring antigen conjugates to treat cancer |
| CN111918668A (zh) * | 2018-02-16 | 2020-11-10 | 王天欣 | 治疗肿瘤细胞和癌症的方法和药剂 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2645866B1 (fr) | 1989-04-17 | 1991-07-05 | Centre Nat Rech Scient | Nouvelles lipopolyamines, leur preparation et leur emploi |
| WO1991014696A1 (en) | 1990-03-29 | 1991-10-03 | Gilead Sciences, Inc. | Oligonucleotide-transport agent disulfide conjugates |
| US5283185A (en) * | 1991-08-28 | 1994-02-01 | University Of Tennessee Research Corporation | Method for delivering nucleic acids into cells |
| US5837533A (en) * | 1994-09-28 | 1998-11-17 | American Home Products Corporation | Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent |
| FR2727679B1 (fr) | 1994-12-05 | 1997-01-03 | Rhone Poulenc Rorer Sa | Nouveaux agents de transfection et leurs applications pharmaceutiques |
| FR2730637B1 (fr) * | 1995-02-17 | 1997-03-28 | Rhone Poulenc Rorer Sa | Composition pharmaceutique contenant des acides nucleiques, et ses utilisations |
| KR19990022597A (ko) | 1995-06-07 | 1999-03-25 | 다니엘 엘. 캐시앙, 헨리 엘. 노르호프 | 티오양이온성 지질, 제약조성물 및 그 사용 방법 |
| FR2741066B1 (fr) * | 1995-11-14 | 1997-12-12 | Rhone Poulenc Rorer Sa | Nouveaux agents de transfection et leurs applications pharmaceutiques |
| US5942634A (en) * | 1997-05-09 | 1999-08-24 | Genzyme Corporation | Cationic amphiphiles for cell transfections |
| EP0945138A1 (en) | 1997-12-04 | 1999-09-29 | Université Louis Pasteur de Strasbourg | Transfection particles |
| US6169078B1 (en) | 1998-05-12 | 2001-01-02 | University Of Florida | Materials and methods for the intracellular delivery of substances |
-
1999
- 1999-01-28 BR BR9907269-6A patent/BR9907269A/pt not_active IP Right Cessation
- 1999-01-28 DE DE69927669T patent/DE69927669T2/de not_active Expired - Lifetime
- 1999-01-28 IL IL13724799A patent/IL137247A0/xx unknown
- 1999-01-28 WO PCT/FR1999/000162 patent/WO1999038821A2/fr not_active Ceased
- 1999-01-28 CN CN99802464A patent/CN1289371A/zh active Pending
- 1999-01-28 EP EP99901639A patent/EP1049793B1/fr not_active Expired - Lifetime
- 1999-01-28 JP JP2000530060A patent/JP2002501762A/ja active Pending
- 1999-01-28 HU HU0101393A patent/HUP0101393A3/hu unknown
- 1999-01-28 KR KR1020007008257A patent/KR20010081924A/ko not_active Ceased
- 1999-01-28 AT AT99901639T patent/ATE306556T1/de not_active IP Right Cessation
- 1999-01-28 CA CA002318512A patent/CA2318512C/fr not_active Expired - Fee Related
-
2000
- 2000-07-04 AU AU43843/00A patent/AU759197B2/en not_active Ceased
- 2000-07-06 US US09/610,727 patent/US6521252B1/en not_active Expired - Fee Related
- 2000-07-28 NO NO20003880A patent/NO20003880L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8021686B2 (en) | Lipid-encapsulated polyanionic nucleic acid | |
| EP1019365B1 (en) | Novel compositions for the delivery of negatively charged molecules | |
| EP2567693B1 (en) | Lipid encapsulated interfering RNA | |
| US10342761B2 (en) | Method of encapsulating a nucleic acid in a lipid nanoparticle host | |
| Bhattacharya et al. | Advances in gene delivery through molecular design of cationic lipids | |
| US5851548A (en) | Liposomes containing cationic lipids and vitamin D | |
| US7422902B1 (en) | Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer | |
| JP6126072B2 (ja) | 遺伝子発現を抑制する治療におけるリポソームによる効率的な送達のプロセスおよび組成物 | |
| EP0901463B1 (fr) | Composes glycerolipidiques utiles pour le transfert d'une substance active dans une cellule cible | |
| EP2892505B1 (en) | Lipid assemblies comprising anionic lysolipids and use thereof | |
| US20070218122A1 (en) | siRNA silencing of influenza virus gene expression | |
| HUE029977T2 (en) | Oligonucleotides to generate a change in the sequence of target RNA molecules present in a living cell | |
| CN101346393A (zh) | 修饰的siRNA分子及其应用 | |
| US5739271A (en) | Thiocationic lipids | |
| CA2271582A1 (en) | Method for administration of therapeutic agents, including antisense, with repeat dosing | |
| JP2002501762A5 (enExample) | ||
| EP1007097B1 (fr) | Formulation de particules agent(s) de transfection cationique(s)/acides nucleiques stabilisees | |
| US20080145413A1 (en) | Lipids and lipid assemblies comprising transfection enhancer elements | |
| EP1938843A1 (en) | Lipids and lipid assemblies comrising transfection enhancer elements | |
| US5759519A (en) | Method for the intracellular delivery of biomolecules using thiocationic lipids | |
| EP2113247A2 (en) | High efficiency encapsulation of nucleic acids in lipid vesicles | |
| US5756352A (en) | Thiocationic lipid-nucleic acid conjugates | |
| Sternberg et al. | Steric stabilization of cationic liposome-DNA complexes: influence on morphology and transfection activity | |
| HK1029578B (en) | Novel compositions for the delivery of negatively charged molecules |